Prolylcarboxypeptidase promotes IGF1R/HER3 signaling and is a potential target to improve endocrine therapy response in estrogen receptor positive breast cancer-Reference-Cited by-同舟云学术

Prolylcarboxypeptidase promotes IGF1R/HER3 signaling and is a potential target to improve endocrine therapy response in estrogen receptor positive breast cancer

Published:2022-11-04 Issue:1 Volume:23 Page:1-10
ISSN:1538-4047
Container-title:Cancer Biology & Therapy
language:en
Short-container-title:Cancer Biology & Therapy

Author:

Duan Lei¹,Calhoun Sarah J.¹,Perez Ricardo E.¹,Macias Virgilia²,Mir Fatima³,Gattuso Paolo³,Maki Carl G.¹^ORCID

Affiliation:

1. Department of Anatomy and Cell biology, Rush University Medical Center, Chicago, IL, 60612, USA

2. Department of Pathology, University of Illinois at Chicago, Chicago, IL, 60612, USA

3. Department of Pathology, Rush University Medical Center, Chicago, IL, 60612, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/15384047.2022.2142008

Reference28 articles.

1. Adjuvant endocrine therapy for premenopausal women with breast cancer

2. Adjuvant Hormonal Therapy for Early-Stage Breast Cancer

3. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

4. A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer

5. Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting AKT Kinase in Hydroxytamoxifen-Resistant Breast Cancer Cells;IECC 2023;2023-03-16